Second Phase 2 Trial of NP001 for ALS Therapy is Underway
Neuraltus Pharmaceuticals has initiated the second Phase 2 clinical trial of NP001 for the treatment of amyotrophic lateral sclerosis (ALS), with the goal of confirming the clinical findings of the previous Phase 2 study in ALS patients with elevated levels of baseline inflammation. The study is currently recruiting…